cheap oakleys quote

Thirty years ago, when the world is facing AIDS the incurable disease, the big pharmaceutical companies perceive opportunities, to develop new drugs.
Today, the world is facing another crisis - germs resistant to antibiotics, and the pharmaceutical industry has taken the opposite strategy, reduce spending on research and development, because of this field to make money a forlorn hope.
Antibiotics by its own success,cheap oakleys. Commonly used as a cheap, antibiotic overuse and too casual, produce antibiotics cannot cure "superbugs".
These "superbugs",fake oakleys; more and more, but has not yet been widely spread, so study their expensive is not worth it. Medical experts point out that the trouble may cause drug back in 1928, Alexander Fleming before the invention of penicillin era.
Industry leaders and public health officials point out that solving the problem needs to be approved faster measures drugs and looking for new ways to ensure enterprise in return.
Johnson & Johnson N: quote), head of the drug Paul Stoffels is better than a lot of people can understand the problem.
In December last year, Johnson & Johnson for the treatment of drug-resistant tuberculosis drug regulatory approval, and provide the solution of the problem with a glimmer of hope.
Unfortunately, this is just a special case, Johnson & Johnson now didn't develop any antibiotics.
"New antibiotic market is small, no returns, so the money will not come in." The Stoffels said in an interview in London.
"The problem is that the absolute amount of people ready to pay for drugs. If it is cancer patients, (per capita) drug spending is likely to be 30000, 50000,cheap oakleys, or $80000, but the antibiotic spending may have only a few hundred dollars."
Astrazeneca investment difficult choices (azn.l) said on Monday that will reduce the development of anti-infection drugs. "We must make a choice, investment we can do is to focus on our direction to think that you can have a major impact." Pascal Soriot chief executive told Reuters.
Drug regulatory approval threshold is a key factor affecting enterprise r&d investment.
Antibiotics for examination and approval of the threshold is very high, 2004, novartis (Ketek beat. PA: quote) for examination and approval of drug scandal is part of the cause of the high threshold, U.S. officials said later, because of the risk of side effects severe disease patients using this drug should be moderated,fake oakleys.
Noticed the recent official caution for new drug development, the United States food and drug administration (FDA), head of the drug, Janet Woodcock last year proposed a "reset" the examination and approval procedures.
 

Related articles：

• The dow Jones denies bribed Chinese officials had access to information in China
• replica oakleys"
• cheap oakleys but if the situation chaos